A. Le Groumellec

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Jean‐Yves Douillard, Rafael Rosell, Mario De Lena et al. · The Lancet Oncology · 2006 · 1.6K citations

Medicine, Oncology, Pharmacology +12

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study

Jean‐Yves Douillard, R. Gervais, G Dabouis et al. · Annals of Oncology · 2004 · 37 citations

Medicine, Oncology, Pharmacology +17

Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice

K. Mattson, Lionel Bosquée, G Dabouis et al. · Lung Cancer · 2000 · 23 citations

Medicine, Oncology, Pharmacotherapy +9

Pr3 ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients (pts)

R. Rosell, M. De Lena, Francesco Carpagnano et al. · Lung Cancer · 2005 · 15 citations

Medicine, Oncology, Pharmacology +14

[Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].

Thierry Le Chevalier, D. Brisgand, Jean Louis Pujol et al. · PubMed · 1996 · 11 citations

Medicine, Oncology, Chemotherapy +7